Cytosorbents (NASDAQ:CTSO) Given Buy Rating at D. Boral Capital

Cytosorbents (NASDAQ:CTSO)‘s stock had its “buy” rating reissued by D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the medical research company’s stock.

A number of other equities analysts have also recently commented on CTSO. HC Wainwright reissued a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a report on Monday, November 11th. StockNews.com began coverage on Cytosorbents in a research note on Saturday. They issued a “hold” rating for the company. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Stock Down 5.2 %

CTSO stock opened at $1.09 on Tuesday. The stock has a market capitalization of $59.60 million, a P/E ratio of -3.03 and a beta of 0.61. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.61. The firm has a 50-day simple moving average of $1.02 and a 200-day simple moving average of $1.04. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.

Institutional Investors Weigh In On Cytosorbents

Large investors have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its position in Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after buying an additional 32,415 shares in the last quarter. Sargent Investment Group LLC increased its stake in shares of Cytosorbents by 13.4% in the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock worth $2,439,000 after acquiring an additional 192,747 shares during the last quarter. Skylands Capital LLC raised its holdings in shares of Cytosorbents by 1.0% during the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock worth $2,531,000 after acquiring an additional 26,195 shares during the period. Millennium Management LLC acquired a new position in shares of Cytosorbents during the 4th quarter valued at about $30,000. Finally, Northern Trust Corp grew its holdings in shares of Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after purchasing an additional 16,701 shares during the period. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.